Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU

Reuters

07/29

Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU

Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555058979"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555058979\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555058979?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555058979","market":"us","top_or_hot":-1,"title":"Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLabcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-29 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0048573561.USD","symbol_name":"FIDELITY AMERICA \"A\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL6bBsMn:1","article_id":"2555058979","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555058979","pubTimestamp":1753786965,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation . This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0048573561.USD":"FIDELITY AMERICA \"A\" (USD) INC","LU0251131958.USD":"FIDELITY AMERICA \"A\" (USD) ACC","LU0251142724.SGD":"Fidelity America A-SGD","LU0742534661.SGD":"Fidelity America A-SGD (hedged)","BK4196":"保健护理服务","BK4588":"碎股","BK4550":"红杉资本持仓","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4585":"ETF&股票定投概念","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LH":"徕博科"},"translate_title":"Labcorp的PGDx elio获得IVDR CE标志™组织完整，扩大整个欧盟个性化癌症护理的可及性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LH":0.9},"content_text":"Labcorp Achieves IVDR CE-Marking for PGDx elio™ Tissue Complete, Expanding Access to Personalized Cancer Care Across the EU\n    \n\n        Labcorp Holdings Inc., a leading provider of comprehensive laboratory services, announced that its PGDx elio™ tissue complete has achieved IVDR CE-marking under the European Union's new In Vitro Diagnostic Regulation (IVDR). This marks it as the first and only test of its kind in the EU to be CE-marked for comprehensive solid tumor profiling. The approval is a significant milestone, expanding access to personalized cancer care for approximately 2.7 million cancer patients annually in the EU. The test's ability to analyze multiple biomarkers with limited tissue samples supports physicians in delivering guideline-based care and accelerates patient management plans. This achievement not only reflects Labcorp's commitment to advancing precision medicine but also provides biopharma partners with a reliable solution for clinical trial strategies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Labcorp Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DC39103) on July 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}